ES2601191T3 - Método para someter a prueba a un sujeto que se cree que está predispuesto a presentar un cáncer metastásico que utiliza las isoformas delta133p53 - Google Patents
Método para someter a prueba a un sujeto que se cree que está predispuesto a presentar un cáncer metastásico que utiliza las isoformas delta133p53 Download PDFInfo
- Publication number
- ES2601191T3 ES2601191T3 ES10731498.1T ES10731498T ES2601191T3 ES 2601191 T3 ES2601191 T3 ES 2601191T3 ES 10731498 T ES10731498 T ES 10731498T ES 2601191 T3 ES2601191 T3 ES 2601191T3
- Authority
- ES
- Spain
- Prior art keywords
- subject
- metastatic cancer
- predisposed
- isoform
- believed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000037819 metastatic cancer Diseases 0.000 title abstract 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title description 16
- 238000012360 testing method Methods 0.000 title description 3
- 102000001708 Protein Isoforms Human genes 0.000 abstract description 11
- 108010029485 Protein Isoforms Proteins 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 210000002751 lymph Anatomy 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 abstract 1
- 238000010998 test method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000002001 anti-metastasis Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4748—Details p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Método de someter a prueba a un sujeto que se cree que presenta una predisposición a presentar un cáncer metastásico que comprende la etapa de: i) analizar una muestra biológica seleccionada de entre el grupo que consiste en médula ósea, suero, plasma, sangre, linfa o células de tejido canceroso o presuntamente canceroso o tejido adyacente del mismo de dicho sujeto para detectar la presencia de una isoforma p53 seleccionada en el grupo que consiste en Δ133p53ß, Δ133p53 y Δ133p53 γ, siendo la presencia de dicha isoforma p53 indicativa de una predisposición a un cáncer metastásico.
Description
5
15
25
35
45
55
65
enzima ligada) al antígeno unido (de estar presente) formando un sándwich de anticuerpo-antígeno-anticuerpo. Los ejemplos de enzimas que pueden ligarse al anticuerpo son: fosfatasa alcalina, peroxidasa de rábano, luciferasa, ureasa y 3-galactosidasa. El anticuerpo ligado a enzima reacciona con un sustrato para generar un producto de una reacción de color para el que se puede someter a ensayo.
En una "ELISA competitiva", se incuba el anticuerpo con una muestra que contenga antígeno (es decir, un péptido de la isoforma p53). Entonces la mezcla de antígeno-anticuerpo se pone en contacto con una fase sólida recubierta con antígeno (es decir, una placa de microvaloración). A mayor antígeno presente en la muestra, menos anticuerpo libre estará disponible para unirse a la fase sólida. Entonces se agrega un anticuerpo secundario marcado (es decir, enzima ligada) a la fase sólida para determinar la cantidad de anticuerpo primario unido a la fase sólida.
En un "ensayo de inmunohistoquímica" se somete a prueba una sección de tejido para proteínas específicas exponiendo el tejido a anticuerpos que sean específicos para la proteína que se esté sometiendo a prueba. Entonces, se visualizan los anticuerpos por medio de una variedad de métodos para determinar la presencia y cantidad de proteína presente. Los ejemplos de los métodos usados para visualizar anticuerpos son, por ejemplo, a través de enzimas ligadas a anticuerpos (es decir, luciferasa, fosfatasa alcalina, peroxidasa de rábano o Pgalactosidasa), o métodos químicos (por ejemplo, sustrato/cromágeno DAB) o anticuerpos marcados oro, fluorescentes por cualquiera de muchos diferentes métodos conocidos por los expertos en la materia.
En otro aspecto, la presente invención se refiere a un método para cribar compuestos antimetastásicos potenciales, que comprenden las etapas de:
a) poner en contacto el compuesto que se va a someter a prueba con una célula que se sabe que expresa una isoforma p53 seleccionada en el grupo que consiste en ∆133p53, ∆133p53γ y ∆133p53β,
b) determinar la presencia de dicha isoforma p53 por un método de detección de dicha isoforma p53 como se describe anteriormente; y
c) seleccionar dicho compuesto como un compuesto para el cáncer antimetastásico potencial si la isoforma p53 no está expresada en la célula.
Opcionalmente, dicho método de cribado puede incluir una etapa adicional d) de someter a prueba el compuesto seleccionado en la etapa c) sobre células, preferentemente células metastásicas, para confirmar las propiedades antimetastásicas del compuesto seleccionado.
Por ejemplo, dicha etapa d) también puede corresponder con el método divulgado en la solicitud de patente internacional WO 2006/134305, es decir, un método que comprende la etapa de: poner en contacto células tumorales que no expresan E-cadherina en su membrana celular con el compuesto seleccionado, y determinar la presencia de E-cadherina en la superficie celular, siendo dicha presencia indicativa de actividad antimetastásica.
Dicha etapa d) también puede corresponder al método divulgado en Smith HW, Marra P, Marshall CJ.J Cell Biol. 25 Ago 2008; 182(4):777-90, es decir, un método para someter a prueba la invasión de células tumorales en matriz de colágeno tridimensional en la presencia del compuesto seleccionado.
Preferentemente, los compuestos que van a ser sometidos a prueba son ARN antisentido o ARN de interferencia (ARNi).
En otro aspecto, la presente divulgación se refiere a un método para la producción de anticuerpos policlonales que reconocen específicamente un polipéptido de la isoforma p53 que consiste en polipéptido ∆133p53, ∆133p53γ y ∆133p53β, en el que dicho método incluye la etapa de:
a) inmunizar un animal mamífero con una cantidad inmunológicamente efectiva de un polipéptido de la isoforma p53 seleccionado en un grupo que consiste en ∆133p53, ∆133p53γ y ∆133p53β, o contra un fragmento de epítopo específico de por lo menos una longitud de 9 aminoácidos de dicho polipéptido, opcionalmente con la preparación de mejora del transportador;
b) opcionalmente, determinar in vitro la presencia de anticuerpos específicos en el suero o plasma del animal; y
c) purificar o aislar el polipéptido específico de anti-∆133p53, anti-∆133p53γ y anti-∆133p53β a partir del suero
o plasma del animal.
También forma parte de la presente divulgación, un método para la producción de una célula de hibridoma que puede secretar anticuerpos monoclonales que reconocen específicamente una isoforma de p53 seleccionada en el grupo que consiste en polipéptidos de ∆133p53, ∆133p53γ y ∆133p53β, en el que dicho método incluye la etapa de:
a) inmunizar un animal mamífero con una cantidad inmunológicamente efectiva de una isoforma p53
11
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22176909P | 2009-06-30 | 2009-06-30 | |
EP09305633A EP2272979A1 (en) | 2009-06-30 | 2009-06-30 | Method for testing a subject thought to be predisposed to having cancer |
EP09305633 | 2009-06-30 | ||
US221769P | 2009-06-30 | ||
PCT/EP2010/059321 WO2011000891A1 (en) | 2009-06-30 | 2010-06-30 | Method for testing a subject thought to be predisposed to having metastatic cancer using delta133p53beta |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2601191T3 true ES2601191T3 (es) | 2017-02-14 |
ES2601191T8 ES2601191T8 (es) | 2017-06-09 |
Family
ID=41119348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10731498.1T Active ES2601191T3 (es) | 2009-06-30 | 2010-06-30 | Método para someter a prueba a un sujeto que se cree que está predispuesto a presentar un cáncer metastásico que utiliza las isoformas delta133p53 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20120115151A1 (es) |
EP (2) | EP2272979A1 (es) |
JP (1) | JP2012531606A (es) |
CN (1) | CN102471801B (es) |
BR (1) | BRPI1011929A2 (es) |
CA (1) | CA2766317C (es) |
ES (1) | ES2601191T3 (es) |
MX (1) | MX341181B (es) |
WO (1) | WO2011000891A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2867368B1 (en) | 2012-07-06 | 2022-01-12 | Institut Gustave Roussy | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
CN102924594B (zh) * | 2012-08-03 | 2014-05-07 | 无锡傲锐东源生物科技有限公司 | 抗肿瘤蛋白p63单克隆抗体及其用途 |
CN102827278B (zh) * | 2012-08-03 | 2014-04-23 | 无锡傲锐东源生物科技有限公司 | 抗肿瘤蛋白p53单克隆抗体及其用途 |
BR112017015204A8 (pt) * | 2015-01-30 | 2021-02-23 | Centre Nat Rech Scient | isoformas de delta133p53beta e delta133p53gama são biomarcadores de células tronco de câncer |
WO2016120493A1 (en) | 2015-01-30 | 2016-08-04 | Centre National De La Recherche Scientifique (Cnrs) | Reprogramming method for producing induced pluripotent stem cells (ipsc) |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
WO1990002809A1 (en) | 1988-09-02 | 1990-03-22 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
JP4146512B2 (ja) | 1991-03-01 | 2008-09-10 | ダイアックス コープ. | 小型タンパク質 |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
DE10234739A1 (de) * | 2002-07-30 | 2004-02-12 | Universitätsklinikum Hamburg-Eppendorf | Splicing-Variante des humanen p53-Proteins und deren Verwendung zur Herstellung pharmazeutischer Präparate zur Behandlung von Tumorerkrankungen |
CN1970763A (zh) * | 2006-12-18 | 2007-05-30 | 北京市结核病胸部肿瘤研究所 | 一种截短的抑癌基因p53增加人肺癌细胞对抗肿瘤药物敏感性 |
WO2009029054A1 (en) * | 2007-08-31 | 2009-03-05 | Agency For Science, Technology And Research | P53 isoform gene(s) and uses thereof |
FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2009
- 2009-06-30 EP EP09305633A patent/EP2272979A1/en not_active Withdrawn
-
2010
- 2010-06-30 JP JP2012518089A patent/JP2012531606A/ja active Pending
- 2010-06-30 CN CN201080029421.7A patent/CN102471801B/zh active Active
- 2010-06-30 ES ES10731498.1T patent/ES2601191T3/es active Active
- 2010-06-30 EP EP10731498.1A patent/EP2449133B1/en active Active
- 2010-06-30 US US13/381,628 patent/US20120115151A1/en not_active Abandoned
- 2010-06-30 MX MX2012000041A patent/MX341181B/es active IP Right Grant
- 2010-06-30 CA CA2766317A patent/CA2766317C/en active Active
- 2010-06-30 WO PCT/EP2010/059321 patent/WO2011000891A1/en active Application Filing
- 2010-06-30 BR BRPI1011929A patent/BRPI1011929A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI1011929A2 (pt) | 2016-04-19 |
ES2601191T8 (es) | 2017-06-09 |
CN102471801B (zh) | 2016-05-11 |
EP2272979A1 (en) | 2011-01-12 |
US20120115151A1 (en) | 2012-05-10 |
CA2766317A1 (en) | 2011-01-06 |
CN102471801A (zh) | 2012-05-23 |
JP2012531606A (ja) | 2012-12-10 |
WO2011000891A1 (en) | 2011-01-06 |
EP2449133A1 (en) | 2012-05-09 |
CA2766317C (en) | 2019-04-02 |
MX341181B (es) | 2016-08-09 |
EP2449133B1 (en) | 2016-08-03 |
MX2012000041A (es) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10705089B2 (en) | Methods and kits for the diagnosis of cancer | |
JP6861771B2 (ja) | 腎疾患のためのマーカー | |
ES2601191T3 (es) | Método para someter a prueba a un sujeto que se cree que está predispuesto a presentar un cáncer metastásico que utiliza las isoformas delta133p53 | |
KR20130000369A (ko) | 단백질 어레이 및 이의 용도 | |
US20210302429A1 (en) | Compositions and methods related to the methylation of histone h1.0 protein | |
JP5703460B2 (ja) | タンパク質含有量の測定方法 | |
US8981066B2 (en) | Epigenetic mechanisms related to DNA damage and aging | |
ES2939643T3 (es) | Proteína Rep como antígeno proteico para su uso en ensayos de diagnóstico | |
JP2023017986A (ja) | 自己抗体の直接イムノアッセイ測定法 | |
WO2008035527A1 (fr) | ANTICORPS MONOCLONAL ANTI-C1q | |
KR20130081952A (ko) | 암 진단용 바이오마커 및 이를 이용한 암세포 분리 방법 | |
US10502731B2 (en) | Use of anoctamin as a biomarker for radiation biodosimetry | |
WO2011147274A1 (zh) | 用于检测生育相关人睾丸和附睾表达305种精子定位蛋白的方法 | |
CN108431032B (zh) | 纤维蛋白原捕捉剂检测ciz1 b变体的用途 | |
KR20160128647A (ko) | 쇼그렌증후군 특이적 항체반응 검사를 이용한 쇼그렌증후군 진단방법 | |
EP3126835B1 (en) | Compositions and methods for identifying ehrlichia species | |
CA2835068C (en) | Method for immunologically measuring soluble lr11 | |
CN116539894A (zh) | Capg在制备病理性心肌肥厚检测试剂中的应用 | |
JP5182684B2 (ja) | カルボキシエチルアルギニンに対する抗体 | |
WO2007038406A1 (en) | Bax expression predicts hematologic disease response to treatment | |
AU2015230872A1 (en) | Markers for renal disease | |
RU2016148914A (ru) | Способ определения специфичности антител |